The growth regulatory protein oncostatin M was initially discovered in macrophage-conditioned medium. We investigated the effects of oncostatin M on cultured rabbit aorta smooth muscle cells (SMCs) and found that the peptide stimulated an increase in the incorporation of [3Hlthymidine into DNA. The magnitude of the stimulation was dependent on oncostatin M concentration and SMC confluency. In subconfluent cultures, 1-2 nM stimulated 4-to 5-fold increases In DNA synthesis after 20 hr. Other structurally related cytokines (granulocyte colony-stimulating factor, leukemia inhibitory factor, interleukin 6, ciliary neurotrophic factor) did not affect SMC DNA synthesis. After 5 or 8 days, oncostatin M caused a doubling in SMC number and also induced a transformed phenotype. The combination of oncostatin M and plateletderived growth factor for 8 days resulted in a 4-fold increase in cell number, approximately the same increase in cell number as induced by the addition of 10% fetid calf serum. Further investigation suggested that the mitogenic effect of oncostatin M was in part due to tyrosine kinase activation. Within 1-2 min, the factor increased phosphotyrosine levels of several SMC proteins. In addition, detectable increases in diacylglycerol levels occurred within 2-5 min, reached 50% above control by 30 min, and remained elevated through 45 min of incubation with oncostatin M. SMC inositol phosphate levels were also elevated within 2 min and then returned to near control values by 20 min. Within 30 min, oncostatin M induced expression of the immdiate-early gene EGR-1. These data indicate that oncostatin M may be an important, naturally occurring mitogen for vascular SMCs.
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Monocyte/macrophages appear to be involved in atherogenesis (reviewed in refs. 1 and 2). They have been reported to adhere to the vessel wall and extravasate at the site of a developing lesion (3) (4) (5) . Once in the subendothelial space they begin to take up modified lipoproteins and store the lipoprotein cholesterol as cholesteryl esters. In the process they become transformed into foam cells, which are characterized by large fatty vesicles (3) . Although the uptake of modified lipoproteins by macrophages is thought to be protective, macrophage/foam cells may also exacerbate the disease process. Recently, Ross and coworkers (6) have shown that human macrophages in vessel wall lesions possess platelet-derived growth factor (PDGF) B protein (6) . In addition, it is well accepted that PDGF chemoattracts and mitogenically stimulates vascular smooth muscle cells (SMCs) . The recruitment and proliferation of SMCs in the plaque could further stimulate progression of the disease by increasing the size of the atheroma. Although the chemoattractant and mitogenic properties of PDGF for SMCs have been characterized (7, 8) , the possible involvement of other macrophage-derived growth factors in atherogenesis has not yet been thoroughly explored.
A growth regulatory protein, oncostatin M, originally found to be secreted by macrophages (9, 10) and T lymphocytes (11) , has been reported to share some structural and functional homology with other hematopoietic and neuropoietic cytokines (12, 13) . The 28-kDa peptide inhibited the proliferation of some tumor cell lines but also stimulated several normal fibroblast lines to proliferate (9, 14) . In addition, the peptide induced the differentiation of some cell types, including stimulation of interleukin 6 production by endothelial cells (15) , up-regulation of the low density lipoprotein receptor in liver cells (16) , and stimulation of acutephase proteins and plasminogen activator in liver cells (17) . Oncostatin M appears to exert these effects upon binding to a specific cell surface receptor (16, 18) and stimulating increases in the levels of phosphotyrosine proteins as well as other second messenger pathways (16, 19) . We investigated the effects ofoncostatin M on cultured rabbit aorta SMCs and found that this polypeptide is a potent SMC mitogen. RNA Isolation and Northern Blot Analysis. The 3.1-kb murine EGR-1 cDNA (kindly provided by V. P. Sukhatme, University of Chicago) was purified from plasmid pUC13 after digestion with EcoRI. The human c-jun cDNA (2.6 kb) was purified from plasmid vector pGEM2 after digestion with EcoRI. The human c-fos genomic probe (9 kb) was purified from plasmid vector pBR322 after digestion with EcoRI. The human -actin cDNA (1.0 kb) and the human c-myc genomic probes (exon 3, 1.2 kb) were kindly provided by Jill Lacy (Yale University, New Haven, CT). For mRNA detection, purified inserts were radiolabeled to a specific activity of 109 cpm/,ug using [32P]dCTP (Amersham) and purified with G-50 Sephadex columns.
MATERIALS AND METHODS
SMCs (-4 x 106 per 100-mm dish) were preincubated with oncostatin M, washed with PBS, and lysed in guanidinium isothiocyanate. Total RNA was isolated by ultracentrifugation through a cesium chloride cushion, separated by electrophoresis in 1.2% agarose gels (10 ,ug per lane) containing 6% formaldehyde, stained with ethidium bromide, and transferred to nitrocellulose membranes (22) . Prehybridization, hybridization, washing, autoradiography, and densitometry were as described (19) . Some blots were stripped and reprobed with y-actin to verify that equivalent amounts ofRNA were being assayed. A morphology that partially resembled the shape of PDGFtreated cells (Fig. 2 C and D) . When the two growth factors were combined, the SMCs appeared to lose contact inhibition and began to overlap (Fig. 2E) . In contrast, cells in 10%o serum exhibited a cobblestone morphology and were clearly contact inhibited (Fig. 2B) . Oncostatin M is a member of a family of related cytokines that include leukemia inhibitory factor, interleukin 6, granulocyte colony-stimulating factor, and ciliary neurotrophic factor, as reported by Rose and Bruce (12) and Bazan (13) . Although many of the biologic properties of these related factors are unique, certain others are shared by two or more members of the family (12, 13) . We decided to test other members ofthe family for their ability to stimulate the growth of rabbit SMCs. The results shown in Table 2 indicate that none of the other related cytokines was able to affect DNA synthesis.
Effect of Oncostatin M on Tyrosine Phosphorylation. It was recently reported that oncostatin M stimulated tyrosine phosphorylation in liver cells (16) . Therefore we investigated the effects of the peptide on SMCs. Oncostatin M induced rapid increases in tyrosine phosphorylation of several proteins. New bands appeared around 150 kDa, at 80 kDa, and at 60 kDa. Additionally, increases in phosphorylation occurred in Az : Cells were plated in 24-well dishes in 1o FBS and DMEM. The next day the media were removed and replaced with DMEM with the indicated amounts ofoncostatin M, leukemia inhibitory factor (LIF), interleukin 6 (IL-6), ciliary neurotrophic factor (CNTF), granulocyte/monocyte colony-stimulating factor (GM-CSF), or granulocyte colony-stimulating factor (G-CSF). After 20 hr, the monolayers were incubated for 2 hr with [3H]thymidine and incorporation of label into DNA was quantitated. Monolayer confluencies were -60%o during incubation with [3H]thymidine.
proteins of 106-130 kDa (Fig. 3A) . The effects of oncostatin M on tyrosine phosphorylation depended on incubation time. At 50 ng/ml, an increase in phosphorylation of the 15S0-kDa protein was observed within 2 min and returned to unstimulated values by 45 min (Fig. 3B) . Protein tyrosine phosphorylation was detectable at concentrations of oncostatin M as low as 5 ng/ml (not shown).
To determine the role of oncostatin M-induced tyrosine phosphorylation in mitogenesis, SMCs were treated with the tyrosine kinase inhibitor (genistein) and a phosphotyrosine phosphatase inhibitor (orthovanadate). Pretreatment of SMCs with genistein (30 ,ug/ml for 45 min) dramatically decreased oncostatin M-stimulated [3Hlthymidine incorporation (Table 3) . On the other hand, pretreatment with orthovanadate (30 AM for 30 min) further enhanced the ability of oncostatin M to increase DNA synthesis (Table 3) . Stimulation of Diacyiglycerol and Inositol Phosphates. It has been reported that phospholipase C-yl activity can be induced by a mechanism that involves tyrosine kinase activation (23) . Therefore, we investigated the effects of oncostatin M on inositol phospholipid-related second messengers. Within 2-5 min of addition, oncostatin M elevated SMC diacylglycerols. The diacylglycerol levels increased by 50%o within 30 min and continued to increase through 45 min of treatment (Fig. 3B) . However, the time dependence for production of inositol phosphates was markedly different. Increases stimulated by oncostatin M had reached a maximum by 2 min and subsided to near baseline values by 20 min of incubation (Fig. 3B) .
Immediate-Early Gene Induction. Since activation of tyrosine kinase has been shown recently to stimulate the transcription of EGR-1, an immediate-early gene induced by growth factors (24), we investigated the effect of oncostatin M on EGR-1 message in SMCs. As shown in Fig. 4 , oncostatin M caused a strong and transient induction ofthe EGR-1 gene. EGR-1 mRNA was induced 10-fold by 30 min and returned to control levels by 2 hr. This immediate/early gene response was inhibited by the tyrosine kinase inhibitor genistein (Fig. 4) .
DISCUSSION
Our results show that the macrophage-derived peptide oncostatin M is mitogenic for rabbit SMCs. The effective concentration range of 0.1-0.4 nM for stimulation of DNA synthesis is similar to the concentration range of PDGF-BBmediated mitogenesis in these cells. The maximal stimulation of DNA synthesis induced by 25 ng of oncostatin M per ml after 20 hr was ==60% of the stimulation induced by 10 ng of PDGF per ml and 30%o of the stimulation induced by fresh serum, suggesting that oncostatin M is not as mitogenically effective as PDGF. However, when cell number was measured after 5 or 8 days of incubation, the two growth factors gave similar increases (=60o of the increase stimulated by serum) at optimal concentrations. In addition, the combination of oncostatin M and PDGF gave cell number increases that were similar to those induced by serum, especially after 8 days of incubation. These results are consistent with the possibility that oncostatin M acts by a unique mechanism and complements the effects of PDGF such that together the two Another interesting finding is that oncostatin M induced an unusual spindle-like morphology, which resembled the morphology of PDGF-treated cells but with distinct differences. Oncostatin M induced longer but thinner pseudopodia compared to PDGF. Furthermore, when the two growth factors were added together, the oncostatin M phenotype appeared to dominate, and the cells lost contact inhibition and began to pile up on each other. This effect became more apparent the longer the cells were maintained in culture in the presence of the two growth factors.
The signal transduction pathways stimulated by oncostatin M appear to have much in common with other growth factors that activate tyrosine kinases. Upon binding PDGF, a tyrosine kinase domain in the cytosolic tail of the PDGF receptor is activated (25) . The 180-kDa PDGF receptor rapidly phosphorylates itself as well as several intracellular enzymes, including GTPase activating protein, phospholipase C-yl, and phosphatidylinositol kinase (3-position) (25) (26) (27) . After phosphorylation, phospholipase C-yl hydrolyzes phosphatidylinositol bisphosphate and generates the intracellular messengers diacylglycerol and inositol trisphosphate (23) . Finally, stimulation of immediate-early gene message appears to be important in the mitogenic mechanism of PDGF (28) . Our results demonstrate that oncostatin M stimulates tyrosine phosphorylation, elevates diacylglycerol and inositol phosphates, and elevates message levels of immediate-early genes. In addition, the elevation of second messengers in the inositol phospholipid degradation pathway suggests that the growth factor causes activation of phospholipase C-yl. In support of this possibility is the finding that one of the phosphotyrosine proteins induced by oncostatin M is %150 kDa, the same size as phospholipase C-yl (23) . The very short time course for the increases in inositol phosphates compared to the longer duration ofelevation ofdiacylglycerol is interesting and has been observed in other pathways ofcell activation (29) . Initially, a rapid stimulation of phosphatidylinositol bisphosphate hydrolysis would increase inositol phosphate levels and diacylglycerol, which would in turn activate protein kinase C (30) . Protein kinase C can further stimulate the activities of degradative enzymes specific for phosphatidylcholine, resulting in the sustained production of diacylglycerol from the degradation of phosphatidylcholine or other non-inositol phospholipids (31, 32) . This more chronic elevation of diacylglycerol has been suggested to play a key role in longer-term cellular activation processes (29) .
The role of tyrosine phosphorylation in the mitogenic mechanism of oncostatin M appears to be important based on studies with inhibitors of tyrosine kinases (genistein) or phosphatases (vanadate). Recently, it has been shown that the tyrosine kinase v-src stimulates the induction of EGR-1 via the activation of the serine-threonine kinase c-raf (24) . In addition, protein kinase C has been shown to cause the induction of EGR-1 and other transacting factors (33) . Oncostatin M may induce EGR-1 by stimulating one or more protein kinase-mediated pathways that converge at the immediate-early gene level. EGR-1 and other transacting factors or immediate-early genes are thought to play a key role in events in the nucleus that result ultimately in initiation of DNA synthesis (28) .
Oncostatin M may be involved in several pathologies associated with leukocytes. The growth factor is derived from activated macrophages (9, 10) and peripheral T lymphocytes (11), both of which are present in atherosclerotic lesions (2) . Macrophages in lesions have been shown to produce PDGF-B (6), which possesses mitogenic (8) Oncostatin M is a member of a family of cytokines and growth factors that share many biologic properties (12, 13) . However, the mitogenic effects of oncostatin M on vascular SMCs appear to be unique. Of the peptides with sequence homologies to oncostatin M (leukemia inhibition factor, ciliary neurotrophic factor, granulocyte colony-stimulating factor) (12, 13) , only oncostatin M increased SMC DNA synthesis. In addition, oncostatin M has been reported to bind to GP-130, the signal-transducing component of the interleukin 6 receptor complex (40) . In rabbit SMCs, IL-6 had no effect on DNA synthesis, suggesting that these cells do not express the second peptide of the IL-6 receptor complex or that the intracellular signal transduced by oncostatin M is different.
Finally, it is likely that multiple growth factors/cytokines expressed by macrophages are involved in processes that lead to SMC involvement in atherosclerosis. Heparin-binding epidermal growth factor (41) and PDGF (6) (7) (8) are secreted by macrophages and have been shown to be potent mitogens for SMCs. Other macrophage-derived growth factors and cytokines have been reported to stimulate SMC proliferation (42, 43) . Our current results suggest that oncostatin M also may be involved in vascular diseases that are characterized by abnormal, proliferative SMCs in the intima. It might be possible to interfere with the development of the disease by inhibiting either the conversion of SMCs to an abnormal phenotype or their abnormal growth by inhibiting the effects of oncostatin M on SMCs.
